| scholarly article | Q13442814 |
| P2093 | author name string | Sherise D Ferguson | |
| Amy B Heimberger | |||
| Tiffany R Hodges | |||
| P2860 | cites work | Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group | Q48271471 |
| Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme | Q48467671 | ||
| Adoptive immunotherapy in patients with recurrent malignant glioma: preliminary results of using autologous whole-tumor vaccine plus granulocyte-macrophage colony-stimulating factor and adoptive transfer of anti-CD3-activated lymphocytes | Q48480362 | ||
| Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens | Q48564522 | ||
| Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2 | Q48589950 | ||
| A vaccine targeting mutant IDH1 induces antitumour immunity | Q48649314 | ||
| Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma | Q49141356 | ||
| Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients | Q53288732 | ||
| Stem cell marker CD133 affects clinical outcome in glioma patients | Q53507481 | ||
| Reduction of end-stage malignant glioma by injection with autologous cytotoxic T lymphocytes. | Q54956863 | ||
| Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. | Q55471514 | ||
| A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma. | Q55474945 | ||
| Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas. | Q55475772 | ||
| Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII | Q55478203 | ||
| Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival | Q56986695 | ||
| Trastuzumab-Induced Cardiomyopathy: Not as Benign as it Looks? A Retrospective Study | Q62476369 | ||
| Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors | Q71805186 | ||
| Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group | Q72234622 | ||
| Isolation of cancer stem cells from adult glioblastoma multiforme | Q81042698 | ||
| NCI-MATCH launch highlights new trial design in precision-medicine era | Q85528297 | ||
| Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 | ||
| Consensus on the role of human cytomegalovirus in glioblastoma | Q24632103 | ||
| Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer | Q24633070 | ||
| An integrated genomic analysis of human glioblastoma multiforme | Q24648860 | ||
| IDH1 and IDH2 mutations in gliomas | Q24648948 | ||
| Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity | Q24652600 | ||
| Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium | Q26765459 | ||
| Molecular testing in lung cancer in the era of precision medicine | Q26824599 | ||
| A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19 | Q26849476 | ||
| Immunotherapy advances for glioblastoma | Q26866513 | ||
| Immunotherapy for primary brain tumors: no longer a matter of privilege | Q27002510 | ||
| CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients | Q27692628 | ||
| Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme | Q27824801 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study | Q27853118 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Human cytomegalovirus infection and expression in human malignant glioma. | Q44991512 | ||
| Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. | Q45918451 | ||
| Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration | Q46720423 | ||
| Systemic T cell adoptive immunotherapy of malignant gliomas | Q47910243 | ||
| Establishment of interleukin 2 dependent cytotoxic T lymphocyte cell line specific for autologous brain tumor and its intracranial administration for therapy of the tumor | Q48237354 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme | Q28087485 | ||
| Cardiac dysfunction in the trastuzumab clinical trials experience | Q28204298 | ||
| Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility | Q28239961 | ||
| I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy | Q28244849 | ||
| A Pilot Study of IL-2Rα Blockade during Lymphopenia Depletes Regulatory T-cells and Correlates with Enhanced Immunity in Patients with Glioblastoma | Q28731711 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma | Q30491742 | ||
| Sleeping Beauty System to Redirect T-cell Specificity for Human Applications | Q30535187 | ||
| Detection of viral pathogens in high grade gliomas from unmapped next-generation sequencing data. | Q30794277 | ||
| Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma | Q33286242 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review | Q33561966 | ||
| Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts | Q33606096 | ||
| Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients. | Q33691858 | ||
| Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy | Q33887448 | ||
| Focal radiation therapy combined with 4-1BB activation and CTLA-4 blockade yields long-term survival and a protective antigen-specific memory response in a murine glioma model | Q33889603 | ||
| The molecular biology of chronic myeloid leukemia. | Q34079452 | ||
| Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial | Q34242939 | ||
| Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. | Q34276759 | ||
| Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma | Q34391844 | ||
| Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma | Q34488771 | ||
| Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulo | Q34666875 | ||
| Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma | Q34722415 | ||
| Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells | Q34760414 | ||
| Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy | Q34764143 | ||
| Major differences between tumor and normal human cell fates after exposure to chemotherapeutic monofunctional alkylator | Q34982828 | ||
| EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma | Q35145144 | ||
| Evaluating many treatments and biomarkers in oncology: a new design | Q35379179 | ||
| Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma | Q35741739 | ||
| Patterns of care and survival for patients with glioblastoma multiforme diagnosed during 2006 | Q35760653 | ||
| Lung cancer in the era of precision medicine | Q35861107 | ||
| Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients | Q35878158 | ||
| Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity | Q36218880 | ||
| RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics | Q36278318 | ||
| Glucocorticoid signaling: a nongenomic mechanism for T-cell immunosuppression | Q36733385 | ||
| Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images | Q36792763 | ||
| Prioritization schema for immunotherapy clinical trials in glioblastoma | Q37078999 | ||
| Transforming Cancer Prevention through Precision Medicine and Immune-oncology. | Q37114360 | ||
| Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. | Q37154132 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. | Q37331928 | ||
| Intracerebral delivery of a third generation EGFRvIII-specific chimeric antigen receptor is efficacious against human glioma. | Q37402375 | ||
| Evaluation of tumor-derived MRI-texture features for discrimination of molecular subtypes and prediction of 12-month survival status in glioblastoma | Q37490196 | ||
| Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management | Q37516733 | ||
| Challenges in clinical design of immunotherapy trials for malignant glioma | Q37640613 | ||
| Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment | Q37970682 | ||
| Vaccine therapies for patients with glioblastoma | Q38243975 | ||
| Current challenges in designing GBM trials for immunotherapy | Q38313826 | ||
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. | Q38317515 | ||
| Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial | Q38386761 | ||
| Significant association of multiple human cytomegalovirus genomic Loci with glioblastoma multiforme samples | Q38407022 | ||
| Precision medicine for metastatic breast cancer--limitations and solutions. | Q38551394 | ||
| Immunomonitoring in glioma immunotherapy: current status and future perspectives | Q38659771 | ||
| Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma | Q38890122 | ||
| Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors | Q39089944 | ||
| BLyS levels correlate with vaccine-induced antibody titers in patients with glioblastoma lymphodepleted by therapeutic temozolomide | Q39434173 | ||
| Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment | Q40400501 | ||
| Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas. | Q40550883 | ||
| T cell adoptive immunotherapy of newly diagnosed gliomas | Q40619438 | ||
| Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors | Q40630013 | ||
| Adoptive immunotherapy of malignant glioma using tumor-sensitized T lymphocytes | Q41491256 | ||
| Exomics and immunogenics: Bridging mutational load and immune checkpoints efficacy | Q41983246 | ||
| Dexamethasone potentiates myeloid-derived suppressor cell function in prolonging allograft survival through nitric oxide | Q42211142 | ||
| Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma. | Q42220581 | ||
| Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response | Q42248504 | ||
| Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression | Q42577764 | ||
| IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. | Q42848152 | ||
| Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study | Q43166491 | ||
| Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study | Q43904522 | ||
| Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index | Q44705970 | ||
| P433 | issue | 3 | |
| P921 | main subject | glioblastoma | Q282142 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 175-186 | |
| P577 | publication date | 2016-05-26 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | CNS oncology | Q26842350 |
| P1476 | title | Immunotherapy in glioblastoma: emerging options in precision medicine | |
| P478 | volume | 5 |
| Q57111067 | Glioblastoma Treatments: An Account of Recent Industrial Developments |
| Q92421241 | Pericytes in Glioblastomas: Multifaceted Role Within Tumor Microenvironments and Potential for Therapeutic Interventions |
| Q90326744 | Responsiveness to anti-PD-1 and anti-CTLA-4 immune checkpoint blockade in SB28 and GL261 mouse glioma models |
| Q48169881 | Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields |
Search more.